Development of Cisplatin Nanoparticles as Dry Powder Inhalers for Lung Cancer
Amrita K. Rao,
Dry powder inhalers offer many advantages in the management, prevention and treatment of various respiratory diseases and
also with tumors associated with lungs. The present study investigated the feasibility of formulating Cisplatin loaded Gelatin nanoparticles
as colloidal drug carriers and converting them into dry powders by coating with inhalable lactose by freeze drying. The average particle
size of Cisplatin gelatin nanoparticles was found to be 314 nm by two step desolvation technique. The mean geometric size of the
carrier particles was found to be 2.8 ± 0.3 µm. Freeze dried nanoparticles were further mixed with various grades of inhalable lactoses
and filled into hard gelatin capsules. In-vitro drug deposition pattern and physicochemical characteristics of nanoparticulate and conventional
dry powder inhaler capsule formulation were compared. Results indicated that the developed gelatin nanoparticulate dry powder
inhaler capsules possessed higher respirable fraction of 31.4% as compared to conventional dry powder capsule formulation.
The present investigation demonstrates that there is a possibility of delivering the nanoparticles to the lungs by incorporating them into
carrier particles by simple adsorption. This provides an innovative path for delivering cytotoxic drugs to the lungs by inhalation.
Keywords: Cisplatin, desolvation, dry powder inhalers, lung cancer, nanoparticles.
Rights & PermissionsPrintExport